| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Indaptus Therapeutics, Inc.$2.63
+0.13 (+5.2%)
F 6Pipeline Score Richly Valued Pharma · Clinical
Market Cap
138.16 M
EPS
-16.05
P/E Ratio
-
Value Trade
210.78 K
-30.86 %
Week
-64.84 %
1 Month
-33.7 %
3 Month
-33.33 %
6 Month
-99.71 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
1.50 M
Monthly Burn
2.34 M
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
59.69 K
52 Week Range
0.92 - 19.91
% held by Insiders
82.39 %
% held by Institutions
0.07 %
Enterprise Value
136.66 M
Total Shares
2.24 M
Short %
9.73 %
Float Shares
1.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Indaptus Therapeutics, Inc.
194Total events
0Upcoming
17Tier-1 (high impact)
2021 – 2026Coverage
Event history 194
May 15, 2026
Q1 2026
●Equity OfferingCorporate
Conversion of Series AA and Series AAA preferred stock into common stock
Mar 31, 2026
Q1 2026
◆Timing GuidancePresentation
Stockholder approval expected for conversion of preferred shares
Q1 2026
◆Runway Guidance UpdateCorporate
Cash and cash equivalents of $5.8 million expected to support operations into Q1 2026
Dec 23, 2025
▼Equity OfferingCorporate
Indaptus enters into $6 million securities purchase agreement with David E. Lazar for convertible preferred stock
Dec 23, 2025
◆Management ChangeCorporate
Avraham Ben-Tzvi joins Board; Hila Kara and Dr. Robert Martell step down
Dec 2025
◆Timing GuidanceDecoy20Presentation
Expects to share more data from combination trial by end of 2025
cancersource ↗
Nov 19, 2025
◆Oral PresentationPresentation
CSO Dr. Michael Newman presents at 3rd Donor Selection & Cell Source Summit
Nov 12, 2025
▲Enrollment CompleteDecoy20Trial
Safety Lead-In cohort enrollment completed with six evaluable participants dosed with Decoy20 and tislelizumab
cancersource ↗
Drug Pipeline Intelligence
F6
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 6%
Micro Cap (rank 857 of 911)
Percentile RankIndaptus Therapeutics, Inc. has significant pipeline risk (6/100), with $71M risk-adjusted pipeline value, led by Decoy20 in Solid Tumor, Adult (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Decoy20 Small molecule | Solid Tumor, Adult | Phase 1 | NCT05651022 | 5% | $71M | ACTIVE NOT_RECRUITING | 120 | VERY_FAST | D (35) | Sep 30, 2027 | HIGH_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Decoy20 | urothelial cancer with liver metastases | — | 2025-09-04 | Partial Response; stable disease; disease progression | Indaptus Therapeutics Provides Clinical Update | |
Decoy20 | urothelial cancer with liver metastases | — | 2025-09-04 | Partial Response; stable disease; disease progression | Indaptus Therapeutics Provides Clinical Update | |
Decoy20 | urothelial cancer with liver metastases | — | 2025-09-04 | Partial Response; stable disease; disease progression | Indaptus Therapeutics Provides Clinical Update |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INDP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INDP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INDP▼ -9.1%on this news· ran to -30% by day 3
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Indaptus Therapeutics reported its financial results for Q1 2026, highlighting a net loss of approximately $2.5 million, down from $4.5 million in Q1 2025. The company is undergoing a management transition and reassessing its development priorities and resource allocation. Additionally, it has completed the conversion of preferred stock into common stock, but faces challenges in raising capital for future operations.
Read more →INDP▲ +6.7%on this news
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Indaptus Therapeutics has entered a $6 million securities purchase agreement with investor David E. Lazar, who will also serve as Co-CEO and Chairman. The agreement involves the issuance of non-voting convertible preferred stock, pending stockholder approval. The company aims to leverage Lazar's expertise to explore strategic opportunities and enhance shareholder value.
Read more →INDP▼ -9.6%on this news· ran to -30% by day 3
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Indaptus Therapeutics announced that Dr. Michael Newman will present at the Donor Selection & Cell Source Summit in San Diego on November 19-20, 2025. His presentation will focus on new research related to the company's Decoy platform, which aims to enhance the potency of donor-derived immune cell therapies. This platform employs killed bacteria to induce and activate key immune cells, addressing challenges in allogeneic immunotherapy. The summit will highlight critical topics related to donor screening and process standardization in the expanding field of cell therapy.
Read more →INDP▲ +6.3%on this news· ran to -17% by day 3shared move
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Indaptus Therapeutics reported its third quarter 2025 financial results, highlighting the completion of a Safety Lead-In cohort for its combination therapy, Decoy20 with tislelizumab. While some participants showed stable disease, enrollment is paused for further efficacy evaluations. The company raised $2.3 million to strengthen its financial position as it continues its Phase 1 study.
Read more →INDP▼ -28.4%on this news· ran to -45% by day 3
Indaptus Therapeutics Provides Clinical Update
Indaptus Therapeutics provided updates on its INDP-D101 clinical trial, reporting a Partial Response in a patient with liver metastases from urothelial cancer using Decoy20 monotherapy. The combination therapy with PD-1 inhibitor tislelizumab is underway, with initial safety results showing mixed outcomes. The company also secured $5.7 million in funding to support its clinical efforts.
Read more →INDP▼ -14.6%on this news· ran to -50% by day 3shared move
Indaptus Therapeutics Provides Clinical Update Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safet
Indaptus Therapeutics has provided a clinical update on its Decoy20 therapy, highlighting a Partial Response in a patient with urothelial cancer during the monotherapy study. The company is also moving forward with a combination study alongside PD-1 inhibitor tislelizumab, where initial safety assessments reveal stable disease in one patient out of three evaluable patients. Despite these developments, disease progression was noted in the other patients, raising concerns. Additionally, Indaptus has strengthened its financial position by raising approximately $5.7 million through the sale of convertible promissory notes.
Read more →INDP▼ -12.2%on this news· ran to -53% by day 3shared move
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
Indaptus Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Jeffrey A. Meckler will provide a corporate overview and is available for one-on-one meetings. The event will be accessible via a live webcast, with a replay available for 90 days post-event.
Read more →INDPIndaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress - NEW YORK (
Indaptus Therapeutics has reported its financial results for Q2 2025, highlighting significant clinical advancements, including the initiation of a Phase 1b/2 trial for its Decoy20 product combined with the PD-1 inhibitor tislelizumab. The company raised $5.7 million through a convertible note placement to support its clinical programs. While Indaptus is making progress in its immunotherapy efforts, it continues to face rising operational costs and has recorded a loss per share. Nonetheless, the leadership remains focused on executing their clinical strategy and expects to share initial trial data later this year.
Read more →INDP▲ +5.9%on this news
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
Indaptus Therapeutics, Inc. has announced an additional sale of $3.4 million in convertible notes and warrants, bringing the total raised to $5.7 million. The funds will be utilized for research and development, particularly for a Phase 1b/2 clinical trial. The notes will mature in July 2026 and have a 6% interest rate.
Read more →INDP▼ -18.3%on this news
Indaptus Therapeutics Announces Reverse Stock Split
Indaptus Therapeutics has announced a one-for-twenty-eight reverse stock split effective after trading on June 26, 2025. This decision aims to increase the per share price to comply with Nasdaq listing requirements and attract institutional investors. Stockholders will receive cash for any fractional shares, and the total outstanding shares will decrease significantly.
Read more →INDPIndaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
Indaptus Therapeutics, Inc. has announced the successful completion of a private placement, raising approximately $2.3 million through the sale of convertible promissory notes and warrants. This effort is part of a larger initiative aiming for up to $5 million in gross proceeds to fund research and development activities. The transaction is led by a healthcare-focused institutional investor, emphasizing confidence in the company's innovative cancer and viral infection treatments. The proceeds from the offering are also intended for working capital and general corporate purposes.
Read more →INDPIndaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Indaptus Therapeutics has initiated the expansion arm of its Phase 1b/2 clinical trial, dosing the first patient with Decoy20 in combination with the PD-1 inhibitor tislelizumab. This trial aims to evaluate safety and early anti-tumor activity in patients with advanced solid tumors. The combination is expected to enhance immune responses, particularly in patients who have not previously benefited from checkpoint inhibitors.
Read more →INDPIndaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update NEW YORK (
Indaptus Therapeutics announced its first quarter 2025 financial results, highlighting advancements in its clinical trials and research programs. The company has initiated an expansion arm of the Phase 1b/2 clinical trial for Decoy20 in combination with Tislelizumab, focusing on safety and anti-tumor activity. Despite a decrease in cash reserves and rising expenses related to research and development, the company reported encouraging safety outcomes and beneficial early signs from clinical data. Additionally, Indaptus enhanced its intellectual property portfolio with new patents in vital markets.
Read more →INDPIndaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
Indaptus Therapeutics announced that its Founder and Chief Scientific Officer, Dr. Michael Newman, will chair and speak at the 6th Annual Cytokine-Based Drug Development Summit. He will present on 'Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy' and lead discussions on pre-clinical models. This reflects the growing recognition of Indaptus's novel approaches in immunotherapy.
Read more →INDP▲ +8%on this news
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
Indaptus Therapeutics has announced that its Chief Medical Officer, Dr. Roger Waltzman, will moderate a panel at the upcoming CMO360 Summit in Boston. The panel, focusing on clinical operations and trial efficiency, emphasizes the company's commitment to improving clinical trial management. CEO Jeffrey Meckler expressed optimism about the event's recognition of their approach. The CMO360 Summit serves as a significant networking platform for biotech Chief Medical Officers, showcasing initiatives to advance medicine development and delivery.
Read more →INDPIndaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
Indaptus Therapeutics has reported positive findings from its Phase 1 trial of Decoy20, noting that the treatment was well-tolerated and showed early clinical benefits in over 20 patients. Weekly dosing resulted in significant immune system activation, with observable changes in immune cell trafficking. The company aims to enhance cancer treatment through both innate and adaptive immune responses. Future trials will explore Decoy20's safety and effectiveness in combination with existing therapies like BeiGene's PD-1 inhibitor.
Read more →INDPIndaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Indaptus Therapeutics has launched a new expansion arm of its Phase 1b/2 clinical trial to investigate the combination of its therapy Decoy20 with BeiGene's PD-1 inhibitor, tislelizumab. The trial aims to assess safety, dose optimization, and initial anti-tumor activity in patients. CEO Jeffrey Meckler highlighted this as a pivotal step for their Decoy platform, which is anticipated to enhance treatment effectiveness against solid tumors. The first phase will prioritize safety before broader enrollment.
Read more →INDPIndaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase
Indaptus Therapeutics reported its financial results for Q4 and the fiscal year 2024, providing an update on their Phase 1 trial of Decoy20. The company successfully enrolled more than 20 patients in a weekly dosing cohort, and initial data indicates promising pharmacodynamic immune activation and stable disease in some patients. Additionally, a favorable safety profile has been observed, encouraging further exploration of Decoy20 both as a monotherapy and in combination therapies. There are plans to initiate a combination study with BeiGene's PD-1 inhibitor tislelizumab and to expand trial sites to enhance patient enrollment.
Read more →INDPIndaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
Indaptus Therapeutics has announced the approval of new patents in China, Japan, and Israel for its Decoy platform, aimed at treating Hepatitis B and HIV. These patents cover the use of Decoy bacteria compositions and combination therapies, highlighting the company's commitment to addressing significant global health challenges. With millions affected by these diseases, the expansion of their intellectual property reinforces the potential impact of their innovative treatments. The approach involves a novel immunotherapy method that shows promise in preclinical studies for both infectious diseases and cancer.
Read more →INDPIndaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit
Indaptus Therapeutics, a clinical-stage biotechnology company, announced that Dr. Michael Newman, its Chief Scientific Officer, will present at the 10th Annual Innate Killer Summit. His talk will cover the Decoy platform's capabilities and ongoing research into its application against tumors. The event is scheduled for March 3-5, 2025, in San Diego, California, and aims to gather experts to advance understanding and treatment strategies involving natural killer (NK) cells in oncology. Indaptus's research promises to contribute to the field of immune-based therapies against cancer.
Read more →INDP▼ -9.5%on this news
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
Indaptus Therapeutics has been granted Clinical Trial Authorization by Health Canada, allowing the expansion of its clinical trial for Decoy20 into Canadian sites. This strategic move is intended to broaden patient recruitment and enhance their clinical research program. According to CEO Jeffrey Meckler, this will not only diversify the data set but also expedite the collection of clinical data. The company also plans to submit an amendment for a combination trial of Decoy20 and Beigene's tislelizumab.
Read more →INDPIndaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Indaptus Therapeutics, Inc. announced a $2.25 million private placement of shares priced at-the-market under Nasdaq rules. The offering includes 2,109,383 shares of common stock along with warrants. The proceeds from this placement are intended to fund the company's research and development efforts as well as general corporate purposes. The closing of the offering is scheduled for January 15, 2025, contingent on customary closing conditions. Additionally, the company's forward-looking statements highlight inherent risks and uncertainties involved.
Read more →INDPIndaptus Therapeutics Provides Year-End Review and Outlook for 2025
Indaptus Therapeutics provided a year-end review highlighting significant advancements in its lead product, Decoy20, during 2024. Key achievements included positive outcomes from clinical trials, particularly in immune response and safety, as well as a strategic partnership with BeiGene for further evaluation of Decoy20’s efficacy in combination with tislelizumab. The company anticipates launching new clinical cohorts in 2025 and expanding their clinical trial locations. Funding of $5.5 million secured in 2024 will support ongoing research efforts aimed at exploring the platform's therapeutic applications.
Read more →INDPIndaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
Indaptus Therapeutics, Inc. has announced a registered direct offering and concurrent private placement expected to raise approximately $2.135 million. The offering includes the sale of shares and unregistered warrants, with the warrants exercisable at $1.05 each for a five-year term. Proceeds from the transaction will primarily be used for research and development, as well as for working capital. The closing of this offering is anticipated around November 25, 2024, pending customary closing conditions.
Read more →INDPIndaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update NEW YORK (
Indaptus Therapeutics reported its financial results for the third quarter of 2024, showing a reduction in research and development expenses and a decrease in losses per share compared to the previous year. The company announced a clinical supply agreement with BeiGene to advance its Decoy20 product candidate in a trial combining it with BeiGene's anti-PD-1 antibody, tislelizumab. While recent data from the ongoing Phase 1 trial is encouraging, Indaptus is also facing challenges, including decreasing cash reserves and ongoing operational costs. The company is actively considering financing options to maintain its operations into early 2025.
Read more →INDPIndaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Indaptus Therapeutics announced the publication of groundbreaking research by Dr. Michael Newman in the journal 'Frontiers in Immunology.' The research details their Decoy platform, particularly Decoy20, which aims to activate both the innate and adaptive immune systems to combat cancer. The study suggests that Decoy20 could improve treatment outcomes by engaging multiple immune pathways while minimizing toxicity typically associated with other therapies. Furthermore, Indaptus is exploring collaboration with BeiGene to integrate Decoy20 with their PD-1 inhibitor, tislelizumab, in clinical trials.
Read more →INDPIndaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Indaptus Therapeutics presented interim safety and pharmacokinetic data at the SITC 2024 annual meeting for its lead compound, Decoy20, from a Phase 1 trial. The data indicated that Decoy20, administered weekly, had a favorable safety profile with mostly mild side effects. Notably, one patient with squamous cell carcinoma exhibited stable disease at their first scan. Moving forward, Indaptus is planning to explore combination treatments with BeiGene's PD-1 inhibitor, further validating their clinical hypotheses.
Read more →INDP▼ -11.4%on this news· ran to -22% by day 1
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
Indaptus Therapeutics announced that CEO Jeffrey A. Meckler will present at two upcoming investor conferences, namely Cure by Deerfield and the ThinkEquity Conference, both taking place in New York City. These presentations, planned for October 28 and October 30, 2024, will include discussions about the company's immune system-activating technology and its product candidates. Mr. Meckler will also hold one-on-one meetings with interested investors to further elaborate on the company's research and development efforts.
Read more →INDP▲ +29.8%on this newsshared move
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
Indaptus Therapeutics has announced a clinical supply agreement with BeiGene for a trial combining their Decoy20 immune stimulant with BeiGene's PD-1 inhibitor tislelizumab, aimed at enhancing cancer treatment effectiveness. Indaptus plans to initiate human trials in 2025 based on promising preclinical results showing high tumor eradication rates. The partnership will leverage BeiGene's expertise and resources, marking a significant milestone in Indaptus’ efforts to develop innovative cancer therapies.
Read more →INDPIndaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data
Indaptus Therapeutics announced the initiation of unrestricted enrollment of patients in its Phase 1 trial of Decoy20, following an examination by the Safety Review Committee that cleared the lower dose. The safety profile observed thus far aligns with expectations, with minor treatment-related adverse events reported. The company's CEO noted the potential for significant impact on cancer immunotherapy and the gathering of critical efficacy data in the coming months. This advancement is seen as a key step toward initiating combination therapy next year.
Read more →INDPIndaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy
Indaptus Therapeutics has announced that its Founder and Chief Scientific Officer, Dr. Michael Newman, will participate in a Lumanity webinar on October 23, 2024. The webinar will focus on the future of innate immunity in cancer immunotherapy, highlighting Indaptus's innovative Decoy20 platform. This platform utilizes killed, non-pathogenic Gram-negative bacteria to stimulate immune responses, potentially targeting cancers that have resisted other therapies. Dr. Newman aims to address challenges and opportunities in the field during this event.
Read more →INDPIndaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Indaptus Therapeutics is set to participate in a fireside chat during the 2024 Maxim Healthcare Virtual Summit, scheduled for October 15-17, 2024. CEO Jeffrey A. Meckler will engage in discussions about the company's advancements in immunotherapy, notably their Decoy platform aimed at combating cancer and chronic infections. The event offers an opportunity for participants to engage in one-on-one meetings with the CEO, fostering deeper investor relationships and insight into Indaptus' ongoing developments.
Read more →INDPIndaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
Indaptus Therapeutics has reported promising new safety data for its Decoy20 clinical program following a review by an independent Safety Review Committee. The company plans to expand patient enrollment for two different weekly dosing regimens, one higher and one lower dose, indicating confidence in the treatment's safety profile. The reported adverse events were mild to moderate and resolved quickly, allowing the trial to proceed as scheduled. Management expresses optimism about Decoy20's potential to enhance tumor regression by activating immune responses effectively.
Read more →INDPIndaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced that its CEO, Jeffrey A. Meckler, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference from September 9 to 11, 2024. The presentation will be available on-demand starting September 9 at 7:00 AM Eastern Time. Mr. Meckler will also be available for one-on-one meetings during the conference, allowing for direct interaction with potential investors. Indaptus continues to emphasize its innovations in immunotherapy and the effectiveness of its Decoy product candidates through pre-clinical successes.
Read more →INDPIndaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update NEW YORK (
Indaptus Therapeutics reported its financial results for Q2 2024, highlighting advancements in its Phase 1 clinical trial for Decoy20. The company completed a $3 million offering to support ongoing operations and is gearing up to increase patient dosing in the trial. CEO Michael Newman noted positive early results from the trial and continued engagement in significant oncology conferences. Despite an increase in expenses and a slight rise in loss per share, Indaptus remains optimistic about its future prospects.
Read more →INDPIndaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement
Indaptus Therapeutics, Inc. announced a $3.0 million registered direct offering and a concurrent private placement of shares with investors. The agreement includes the issuance and sale of 1,643,837 shares of common stock at a purchase price of $1.825 each. The funding aims to support research and development activities and provide working capital. The offering is expected to close by August 8, 2024, pending customary conditions.
Read more →INDPIndaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit
Indaptus Therapeutics, a clinical stage biotechnology company, is set to present initial clinical data on its lead product candidate, Decoy20, at the upcoming STING & TLR-Targeted Therapies Summit in June 2024. The Chief Scientific Officer, Dr. Michael Newman, will reveal data that further validates the company's 'Pulse-Prime' hypothesis. Additionally, Dr. Newman has been appointed as chair of the summit for the second year in a row, reflecting his expertise in the field. The company aims to highlight its advancements in immunotherapy designed for both cancer and viral infections.
Read more →INDPIndaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
Indaptus Therapeutics announced that its Chief Medical Officer will present new data regarding Decoy20 at the upcoming Next-Gen Immuno-Oncology Conference. This decoy platform, which utilizes killed bacteria to stimulate immune responses, is currently being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors. The preliminary results demonstrate promise, leading to an optimistic outlook from the company's leadership. The conference serves as an important venue for sharing advancements in the field of immuno-oncology.
Read more →INDP▲ +18.1%on this newsshared move
Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
Indaptus Therapeutics has released promising updated data from its ongoing Phase 1 trial of Decoy20, presented at the ASCO Annual Meeting. The findings indicate that Decoy20 effectively induces immune responses with a manageable safety profile, suggesting potential benefits for patients with advanced solid tumors. The trial showed rapid clearance of the drug from patients' blood and a consistent immune response across different dosage groups. The company's approach could significantly enhance treatment options in a field lacking effective therapies.
Read more →INDP▼ -10.1%on this newsshared move
Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference
Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced that its CEO, Jeffrey Meckler, and CMO, Dr. Roger Waltzman, will present a corporate overview at the Jefferies Global Healthcare Conference scheduled for June 5-6, 2024. The presentation aims to highlight the company's innovative cancer and viral infection treatments, particularly its Decoy technology, which has demonstrated promising results in pre-clinical studies. Additionally, one-on-one meetings will be available for interested parties during the conference, enhancing investor engagement.
Read more →INDP▲ +12.2%on this newsshared move
Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting
Indaptus Therapeutics will present data from its Phase 1 clinical trial for Decoy20 at the American Society of Clinical Oncology Annual Meeting on June 1, 2024. Preliminary results show that Decoy20 rapidly clears from the blood while inducing a significant immune response. The treatment demonstrated a tolerable safety profile associated with immune stimulation. Indaptus plans to continue the trial with a multi-dose cohort, promising further updates on progress throughout the year.
Read more →INDP▲ +5.5%on this news
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
Indaptus Therapeutics announced the dosing of the first patient in the multi-dose phase of its Phase 1 clinical trial for Decoy20, an innovative immuno-oncology therapy. This investigational treatment aims to activate both innate and adaptive immune responses to tackle various advanced solid tumors, including liver and pancreatic cancers. The initial safety data, which will be presented at the ASCO meeting, have been encouraging. The company highlights a significant medical need and believes Decoy20 could offer a unique, broad approach compared to current therapies.
Read more →INDPIndaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on
Indaptus Therapeutics has reported its financial results for the first quarter of 2024, noting a decrease in development and administrative expenses. The company is preparing to present initial results from its Phase 1 clinical trial of Decoy20 at the ASCO annual meeting. Despite a reduction in cash reserves compared to the previous year, Indaptus remains optimistic about its clinical progress and potential for growth. The current financial strategies and ongoing assessments regarding funding options are critical for sustaining operations through upcoming quarters.
Read more →INDP▲ +9.1%on this news
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
Indaptus Therapeutics showcased positive mechanism of action data at the AACR Annual Meeting, specifically highlighting its Decoy platform's ability to engage various immune cell types. The findings indicate that this technology could significantly enhance immune responses against tumors. The company has also begun a multi-dose Phase 1 clinical trial for its treatment, Decoy20. This data aligns with their preclinical studies, increasing confidence in the treatment's potential as an effective immunotherapy.
Read more →INDP▼ -10%on this news
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
Indaptus Therapeutics, a clinical stage biotech firm, will present at the MedInvest Biotech & Pharma Investor Conference on April 3-4, 2024. CEO Jeffrey Meckler will outline the company's innovative therapies that harness the immune system to treat cancer and viral infections. The conference offers a platform for the company to connect with investors and share advancements in their Decoy product candidates. These candidates have shown promising results in pre-clinical studies for eradicating various cancers and chronic viral infections. Indaptus aims to update stakeholders on their developments in these challenging fields.
Read more →INDP▲ +6.9%on this news· ran to +21% by day 1shared move
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
Indaptus Therapeutics announced promising data from its Decoy platform, which demonstrates activation of various immune cells critical for anti-tumor responses. This data will be presented at the upcoming AACR Annual Meeting. The findings indicate that Decoy bacteria can induce immune cell activation while minimizing potential toxicity. The results are significant for the ongoing Phase 1 clinical trial of Decoy20, supporting its therapeutic potential in treating solid tumors.
Read more →INDPIndaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
Indaptus Therapeutics, a clinical stage biotechnology company, will participate in a webinar hosted by Tribe Public on March 20, 2024. CEO Jeffrey Meckler will present and engage in a Q&A session regarding the company's unique approach to immunotherapy for cancer and viral infections. This event aims to enhance awareness of Indaptus' innovative treatments and will be accessible to interested participants with prior registration required.
Read more →INDPIndaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patient
Indaptus Therapeutics reported its financial results for Q4 and the fiscal year 2023, highlighting positive developments in its ongoing Phase 1 clinical trial for Decoy20. Encouraging results were noted from the second cohort, leading to the initiation of a multi-dose study aimed at assessing the treatment's safety and potential efficacy against tumors. The company's financials reveal increased expenses, but it maintains a stable cash position to support operations through mid-2024, emphasizing prudent financial management.
Read more →INDP▲ +12.9%on this news
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
Indaptus Therapeutics has announced positive results from the second cohort of its Phase 1 trial for Decoy 20, leading to a recommendation for initiating a multi-dose cohort from an independent Safety Review Committee. The positive outcomes suggest a strong immune response in patients akin to that of the first cohort. The company plans to start patient screenings for multiple doses, with the trial's aim to evaluate safety and efficacy against various types of cancer. Data from the single-dose cohort is expected to be presented at a scientific conference in 2024.
Read more →INDPIndaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Indaptus Therapeutics, a clinical-stage biotechnology company, announced its participation in the 2024 BIO CEO & Investor Conference scheduled for February 26-27, 2024. CEO Jeffrey A. Meckler and CFO Nir Sassi will provide a corporate update focusing on the company's advancements in immunotherapy for cancer and viral infections. Their novel approach utilizes immune system activation strategies, which have shown promising pre-clinical results across various cancer types and infections. The presentation aims to outline Indaptus' strategic vision for the future.
Read more →INDPIndaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
Indaptus Therapeutics, Inc. has launched new social media channels to improve engagement and share updates about its cancer and viral infection treatments. The company aims to foster open communication and education regarding its innovative immunotherapy, which is currently in Phase 1 clinical trials. CEO Jeffrey Meckler emphasized the importance of creating a community passionate about medical advancements. This initiative reflects Indaptus' commitment to transparency and provides a platform for sharing valuable insights with various stakeholders.
Read more →INDP▲ +7.2%on this news
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update NEW YORK (
Indaptus Therapeutics announced its third-quarter 2023 financial results, revealing progress in its clinical trials, particularly the INDP-D101 trial of Decoy20 for treating solid tumors. The company reported that all patients in the first cohort maintained stable disease and that immune activation was evident. They have begun dosing in the second cohort at a lower dose and expect results to guide Phase 2 dosing decisions. Financially, R&D expenses increased compared to the previous year, and the company is managing its cash position as it anticipates ongoing operating needs into the second quarter of 2024.
Read more →INDP▲ +7.2%on this news
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
Indaptus Therapeutics has released interim results from its Phase 1 study of Decoy20, revealing a significant immune response with over 50 cytokines and chemokines produced after a single dose in the first patient cohort. Participants experienced stable disease after four weeks, with generally tolerable adverse events. The data suggests the potential for Decoy20 to activate both innate and adaptive immune systems effectively. The ongoing study seeks to refine dosing and assess additional biomarkers in future cohorts.
Read more →INDPIndaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
Indaptus Therapeutics has announced the presentation of positive interim results from the first cohort of its Phase 1 study on Decoy20, a compound targeting advanced solid tumors. As of August 31, 2023, all four patients exhibited activation of immune biomarkers and stable disease at one month post-treatment. The company highlights the tolerability and rapid clearance of Decoy20, aligning with its 'Pulse-Prime' hypothesis. Full results will be presented at the upcoming Society for Immunotherapy of Cancer meeting.
Read more →INDPIndaptus Therapeutics to Present at the LD Micro Main Event XVI
Indaptus Therapeutics, Inc. announced that CEO Jeffrey A. Meckler will present a corporate overview at the LD Micro Main Event XVI, taking place from October 3-5, 2023, in Los Angeles. The live presentation is expected to provide insights into the company's product candidates and strategic vision, with a replay available post-event. The company's innovative Decoy technology has shown promise in pre-clinical studies against various cancers and chronic infections. The event highlights Indaptus's efforts to engage with investors and share the progress of its research initiatives.
Read more →INDP▲ +7.3%on this news· ran to -26% by day 3
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
Indaptus Therapeutics has commenced dosing the first patient in the second cohort of its Phase 1 trial for Decoy20, a treatment aimed at advanced solid tumors. This lower dose follows positive pharmacodynamic effects noticed in the previous cohort. The trial will assess safety, tolerability, and dosing for future phases. The company's approach focuses on activating immune responses to fight cancer by using a unique decoy technology.
Read more →INDPIndaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Indaptus Therapeutics, Inc. will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, taking place from September 11 to 13, 2023. CEO Jeffrey A. Meckler is scheduled to provide a corporate overview on September 13, and will be available for one-on-one meetings throughout the conference. The company focuses on novel immunotherapy solutions and has demonstrated promising results in pre-clinical studies, positioning itself for future development opportunities.
Read more →INDP▲ +7.8%on this news
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update NEW YORK (
Indaptus Therapeutics reported its financial results for the second quarter of 2023, highlighting the completion of the first patient cohort in the INDP-D101 trial for Decoy20. The company has received authorization to move into the second cohort based on observed immune activation. Indaptus appointed Roger Waltzman, M.D. as Chief Medical Officer to leverage his industry expertise. Financially, the company noted a decrease in cash reserves and an increase in operational expenses, raising concerns about its cash position for ongoing activities into 2024.
Read more →INDP▲ +22.8%on this newsshared move
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
Indaptus Therapeutics has announced the successful completion of the first cohort in its Phase 1 trial for Decoy20, which exhibited a notable immune response. Following a safety review, the company received approval to continue its study with the next cohort of patients. While some adverse events were reported, they were short-lived and consistent with the treatment's mechanism of action. The ongoing analyses aim to inform the Recommended Phase 2 dose for subsequent studies planned for 2024.
Read more →INDPIndaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer
Indaptus Therapeutics has appointed Dr. Roger Waltzman as its Chief Medical Officer, effective August 7, 2023. With a strong background in drug development and immuno-oncology, Waltzman joins the company amid ongoing trials of its Decoy platform. CEO Jeffrey Meckler expressed confidence in Waltzman's ability to significantly impact Indaptus’s development programs. The company aims to advance its unique approach to immunotherapy based on promising preclinical results.
Read more →INDPIndaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference
Indaptus Therapeutics, a biotechnology firm focused on transformative therapeutics, announced that CEO Jeffrey A. Meckler will participate in the Maxim Group Virtual Healthcare Conference from June 20 to 22, 2023. Mr. Meckler's fireside chat with Jason McCarthy from Maxim Group is scheduled for June 21 at 10:30 am ET. The company boasts a novel immunotherapy approach leveraging multi-targeted immune activation strategies and has shown promising results in pre-clinical studies against several cancers and chronic viral infections.
Read more →INDPIndaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023
Indaptus Therapeutics, Inc. is set to present a corporate overview at the Jefferies Healthcare Conference 2023, scheduled for June 9. CEO Jeffrey A. Meckler will provide insights into the company's strategies and innovations in immunotherapy. The participation in this prominent healthcare event reflects the company's efforts to connect with investors and stakeholders. Attendees will have the opportunity for one-on-one meetings with the CEO, enhancing engagement prospects.
Read more →INDP▼ -9.3%on this news
Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March
Indaptus Therapeutics reported its financial results for Q1 2023, highlighting the dosing of the first patient in the Phase 1 trial of Decoy20 targeting solid tumors. The company presented significant research data at the American Association for Cancer Research conference and expanded its intellectual property portfolio. However, they reported a rise in operational expenses and indicated a substantial cash outflow, necessitating careful cash management as they advance their clinical trials.
Read more →INDPIndaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit
Indaptus Therapeutics has announced that its Chief Scientific Officer, Dr. Michael Newman, will chair the upcoming 4th STING & TLR-Targeting Therapies Summit and deliver two presentations. His talks will focus on breakthroughs using the company's Decoy platform for cancer treatment and targeting hepatitis B virus infection. This event marks a significant opportunity for Indaptus to engage with leaders in the field and foster discussion on innovative treatment strategies. The summit is expected to draw over 100 participants from biotech and academia, highlighting the importance of advancements in innate immune therapies.
Read more →INDP▼ -7.8%on this news
Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023
Indaptus Therapeutics announced that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023, scheduled for April 25-27, 2023. The presentation aims to highlight the company's advancements in transformative therapeutics and immunotherapy. Mr. Meckler will also be available for one-on-one meetings during the event, fostering connections with potential investors and partners.
Read more →INDP▲ +23.2%on this newsshared move
Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023
Indaptus Therapeutics presented promising preclinical data for its Decoy anti-tumor immunotherapy platform at the AACR 2023 conference. The findings revealed that Decoy10 effectively reduced tumor growth and metastasis, demonstrating durability in tumor regressions. The research highlighted its potential to activate various immune pathways and its applicability across multiple cancer types. These results indicate a significant advancement in immunotherapeutic strategies aimed at enhancing the body’s immune response against cancer.
Read more →INDPIndaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform
Indaptus Therapeutics has announced the receipt of a patent allowance for its Decoy immunotherapy platform from the National Institute of Industrial Property of Brazil. This development signifies the international expansion of its intellectual property rights, adding value for shareholders. The company is also actively enrolling participants in its Phase 1 clinical trial for the INDP-D101 treatment in solid tumors and anticipates sharing data updates in the future. CEO Jeffrey Meckler praised the growing global recognition of their patented technology.
Read more →INDPIndaptus Therapeutics to Present at the Investor Summit Conference
Indaptus Therapeutics, Inc. announced its participation in the virtual Investor Summit Conference scheduled for March 29, 2023. CEO Jeffrey A. Meckler will present a corporate overview during the event and will be available for one-on-one meetings throughout the conference. The company is focused on developing transformative therapeutics, particularly in immunotherapy, with a unique approach aimed at activating immune responses against various cancers and viral infections.
Read more →INDP▲ +6.3%on this newsshared move
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dos
Indaptus Therapeutics announced its financial results for Q4 and the fiscal year ended December 31, 2022, while providing a corporate update on its clinical activities. The company has successfully dosed the first patient in its Phase 1 trial of Decoy20 for solid tumors, with further enrollment expected as trial sites expand. Although operational costs have increased significantly, Indaptus expects its financial resources to sustain ongoing activities through mid-2024.
Read more →INDPIndaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023
Indaptus Therapeutics, Inc. announced that the American Association for Cancer Research has accepted an abstract regarding its Decoy anti-tumor platform for presentation at their annual conference in April 2023. The research will showcase a novel therapeutic approach utilizing a systemically administered anti-tumor immunotherapy aimed at activating the immune system. This poster presentation highlights the company’s advancements in immunotherapy based on pre-clinical studies demonstrating potential efficacy against various cancer types and chronic viral infections. The acceptance underscores the platform's relevance in the ongoing cancer research discussions.
Read more →INDPIndaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
Indaptus Therapeutics has announced the activation of the Emory Winship Cancer Institute as a clinical trial site for its ongoing Phase 1 clinical trial of Decoy20, aimed at patients with advanced solid tumors. The trial, which is designed to evaluate the safety, tolerability, and efficacy of Decoy20, is accepting patients who have not responded to existing treatment options. This expansion marks a significant step in Indaptus' efforts to advance its clinical trials and potentially address significant medical needs in oncology. The company plans to activate additional trial sites in the coming weeks to expedite data collection.
Read more →INDPIndaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
Indaptus Therapeutics has initiated dosing in its Phase 1 clinical trial for Decoy20, targeting patients with advanced/metastatic solid tumors. The first subject has been administered the drug, showing manageable adverse events consistent with immune activation. The trial aims to evaluate the safety and tolerability of Decoy20, with plans for additional patient enrollment after safety assessments. The study's outcomes may influence further development of Indaptus's therapeutic approaches in oncology.
Read more →INDPIndaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
Indaptus Therapeutics has announced the appointment of Robert Martell, M.D., Ph.D. to its Board of Directors. Dr. Martell brings over 20 years of pharmaceutical experience, previously holding significant roles at Curis, Epi-Cure Pharmaceuticals, and major pharmaceutical companies such as Bayer and Bristol-Myers Squibb. His expertise in oncology and drug development is expected to guide Indaptus as it advances its therapeutic platforms, particularly the Decoy technology aimed at cancer treatment.
Read more →INDPIndaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
Indaptus Therapeutics has announced the activation of Morristown Medical Center as a new clinical trial site for its ongoing Phase 1 trial of INDP-D101. This trial evaluates Decoy20, a treatment for patients with advanced solid tumors who have exhausted other options. The addition of this site is expected to facilitate quicker patient enrollment and accelerate the generation of initial data points essential for the development of this treatment. The trial's primary aim is to assess the safety and tolerability of Decoy20 among enrolled patients.
Read more →INDP▲ +9.5%on this news
Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the initiation of INDP-D101, its first-in-h
Read more →INDPIndaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Company Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 NEW YORK (
Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 YORK (November 10, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or t
Read more →INDPIndaptus Therapeutics to Present at the LD Micro Main Event XV
NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the LD Micro Main Event XV. The conference is being held on October 25 – 27, 2022 at the Lu
Read more →INDPIndaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference. The conference is being held
Read more →INDPIndaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiat
Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022
Read more →INDPIndaptus Therapeutics to Present at JMP Securities Life Sciences Conference
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the JMP Securities Life Sciences Conference on
Read more →INDPIndaptus Therapeutics to Present at Jefferies Healthcare Conference
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the Jefferies Healthcare Conference on Friday,
Read more →INDP▲ +18.8%on this news
Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors NEW YORK (
Therapeutics Announces FDA Clearance of Investigational New Drug to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors YORK (May 19, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), today announced that the U.S. Food and Drug Administra
Read more →INDPIndaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the H.C. Wainwright Global Investment Conference
Read more →INDPIndaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial
Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half
Read more →INDPIndaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 2nd Annual Chronic HBV Drug Development Summit taking pla
Read more →INDPIndaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference
Read more →INDPIndaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update NEW YORK (
Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and YORK (March 21, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), today announces financial results for the fourth quarter and year ended December 31, 2021 and provides a
Read more →INDP▲ +6.7%on this newsshared move
Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit
NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present and participate in a panel discussion at the 3rd Annual STING &
Read more →INDP▼ -7.7%on this news
Indaptus Therapeutics to Present at 34th Annual ROTH Conference
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in an on demand pre-recorded presentation at the 34th Annual ROTH Conference whic
Read more →INDP▼ -8.6%on this news
Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conf
Read more →INDP▲ +8.2%on this newsshared move
Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience On Track to Initiat
Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience Track to Initiate Phase 1 Study of Decoy20 in 2022 YORK (January 3, 2022) - Indaptus Therapeut
Read more →INDP▼ -10.1%on this news
Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors
NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces the appointment of Mark Gilbert, M.D., to its Board of Directors. Dr. Gilbert served as Chief Medical Officer of Juno Therapeutics prior to its ac
Read more →INDPIndaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update NEW YORK (
Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update YORK (November 15, 2021) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), today announces financial results for the third quarter ended September 30, 2021 and prov
Read more →INDP▲ +52.1%on this news
Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s platform technology. The
Read more →INDPIntec Closes Merger with Decoy Biosystems Completes $30 Million Private Placement Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus
Intec Closes Merger with Decoy Biosystems $30 Million Private Placement Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus YORK, Aug. 3, 2021 /PRNewswire/ -Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company," and formerly, Intec Parent, Inc.
Read more →Competitive Position
How INDP ranks across every disease it competes inCompetitive Position is a premium feature
See how INDP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial